Can anifrolumab calm the painful boils of HS? a new trial seeks answers.

This study tests whether anifrolumab, an antibody drug, can reduce skin abscesses and nodules in people with hidradenitis suppurativa (HS). Fifteen adults with moderate-to-severe HS will receive the drug intravenously over 24 weeks. The main goal is to see if at least half of participants achieve a 50% reduction in inflammatory lesions by week 12, while also monitoring safety and quality of life.